Ticker

No recent analyst price targets found for NHS.

Latest News for NHS

Ventripoint Diagnostics' VMS+ Technology Selected for World-First AI Cardiac Monitoring Study in Breast Cancer Patients

Ventripoint's VMS+ platform to be evaluated alongside a second AI technology in a landmark NHS study exploring earlier detection of chemotherapy-related heart damage   Toronto, Ontario – TheNewswire – July 20, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in the application of artificial intelligence to echocardiography, today announced that its VMS+ technology…

TheNewswire • Jul 20, 2026
NHS: Stay Away From This 17% Yielder As Rates Rise (Rating Downgrade)

Neuberger High Yield Strategies Fund is downgraded to a sell due to persistent NAV erosion and unsustainable distributions. NHS trades at a 6.6% discount to NAV and offers a 17.4% yield, but earnings consistently fail to cover payouts, risking further capital deterioration. Leverage at 26.7% and 98% below-investment-grade exposure amplifies risks in a rising rate and higher default environment.

Seeking Alpha • Jul 1, 2026
NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION

NEW YORK, June 30, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on July 31, 2026, has a record date of July 15, 2026, and has an ex-date of July 15, 2026.

PRNewsWire • Jun 30, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for NHS.

No House trades found for NHS.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top